Steven Chamow, Ph.D
Senior Vice President, CMC
Steven Chamow, Ph.D., is Alira Health’s Senior Vice President, CMC Development. Dr. Chamow is an experienced biotechnology executive and consultant, with more than 33 years of biopharmaceutical experience. Previously, he founded Chamow & Associates and acted as President and Principal Consultant prior to the firm’s 2021 acquisition by Alira Health. In this role, Dr. Chamow drew on his extensive technical and product development background to assist biotechnology companies in designing and developing CMC strategies for products in development, including transfer to and implementation by qualified CDMOs.
Before founding Chamow & Associates, Dr. Chamow served as Senior Vice President, CMC at Intradigm Corporation, a private biopharmaceutical company focused on developing RNAi Therapeutics (acquired by Silence Therapeutics). Prior to Intradigm, Dr. Chamow was Vice President, process sciences, at Genitope Corporation and at Abgenix, Inc. (acquired by Amgen), where he built the company’s process sciences department and co-led the design and construction of Abgenix’s award-winning mammalian-cell production facility in Fremont, CA. Before Abgenix, Dr. Chamow served as Director of Biopharmaceutical Development at Scios, Inc., (acquired by Johnson & Johnson), and as a Scientist and Senior Scientist in Process Development at Genentech.
Dr. Chamow was educated at the University of California, earning a B.A. in biology from UC Santa Cruz and a Ph.D. in biochemistry from UC Davis. He completed his postdoctoral training at the National Institutes of Health. Dr. Chamow is an inventor on fourteen issued patents and has contributed to the development of four marketed products (Avastin®, Natrecor®, Vectibix®, Zadaxin®). He has co-authored 49 original research and review articles in peer-reviewed journals and co-edited two books: “Antibody Fusion Proteins” and “Therapeutic Fc Fusion Proteins.”